For the Inventor, By the Inventor

Enter assignee name

Wilmington, DE, United States of America

Beta Pharma, Inc.

USPTO Granted Patents = 17

% Expired Patents = 17.6

EPO Patents = 9

Trademarks = 3

Forward Citations = 17

Loading Chart...

Loading Chart...

20 inventors (with patents filed for the assignee):

Don Zhang (17 out of 17 patents)

Jirong Peng (13 out of 13 patents)

Michael Nicholas Greco (12 out of 46 patents)

4. Michael John Costanzo (12 out of 12 patents)

5. Michael Alan Green (8 out of 23 patents)

6. Victoria Lynn Wilde (8 out of 8 patents)

7. Guojian Xie (4 out of 4 patents)

8. Yinxiang Wang (3 out of 15 patents)

9. Charles Davis (3 out of 3 patents)

10. Wei He (2 out of 123 patents)

11. Yunyan Hu (2 out of 15 patents)

12. Bin Han (2 out of 17 patents)

13. Wei Long (2 out of 19 patents)

14. Lieming Ding (2 out of 14 patents)

15. Fenlai Tan (2 out of 8 patents)

17 patents: Sort by Forward Citations

1. 12595246 - Crystalline and amorphous forms of N-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof (2026-04-07),

2. 12390464 - Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitors (2025-08-19),

3. 12258365 - Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof (2025-03-25),

4. 12187707 - Pharmaceutical formulations of-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereof (2025-01-07),

5. 11414401 - Substituted 2-anilinopyrimidine derivatives as EGFR modulators (2022-08-16),

6. 11352341 - 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof (2022-06-07),

7. 11180478 - Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof (2021-11-23),

8. 11052086 - 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers (2021-07-06),

9. 10844045 - Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof (2020-11-24),

10. 10590111 - Substituted 2-anilinopyrimidine derivatives as EGFR modulators (2020-03-17),

11. 10239864 - 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof (2019-03-26),

12. 9878994 - 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof (2018-01-30),

13. 9820721 - Aspiration and biopsy needle apparatus and devices and applications thereof (2017-11-21),

14. 9359370 - Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof (2016-06-07),

15. 9163010 - Indolinone protein kinase inhibitors (2015-10-20),

Beta Pharma, Inc. is a leading pharmaceutical company specializing in the research, development, and manufacturing of innovative and high-quality medications. With a commitment to improving global health, Beta Pharma strives to provide affordable and accessible healthcare solutions worldwide. Through cutting-edge technologies and a dedicated team of experts, they ensure the safety, efficacy, and reliability of their products. Visit their website for more information.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Beta Pharma, Inc.

17 Patents

#237 in Wilmington, DE

#299 in Delaware

#18,865 in US

#35,857 in the World

Wilmington, DE, United States of America

Beta Pharma, Inc.

Forward Citations = 17

20 inventors:

Don Zhang (17 out of 17 patents)

Jirong Peng (13 out of 13 patents)

Michael Nicholas Greco (12 out of 46 patents)

4. Michael John Costanzo (12 out of 12 patents)

5. Michael Alan Green (8 out of 23 patents)

Please report any incorrect information to [email protected]

Loading…